Viridian Therapeutics, Inc.

NASDAQ:VRDN

Biotechnology

Healthcare
$30.12 -0.88%

-$0.15 today

Market cap
$3.42B
Beta
0.90
P/E (TTM)
-4.7
EPS (TTM)
-$3.53
52W Low $13.18High $34.29

Volume 1.49M

Average 2.86M

VRDN Debt Repayment

Cash used to repay borrowings during the period.

Viridian Therapeutics, Inc.NASDAQ: VRDN

Debt Repayment · Q2 FY2026 · quarter ended Jun 2026

Debt repayment outflow grows to $195.3M

Q2 FY2026 debt repayment was $195.3M, compared with $0 a year earlier. Trailing-twelve-month debt repayment was $224.18M. Over 3 fiscal years it compounded at +79.4% a year.

Context

  • Debt repayment amounted to 40.8% of revenue in FY2025, up 40.8 pp from a year earlier.
  • Debt repayment increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near $195.3M or moves back toward the trailing-twelve-month quarterly average of $56.04M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$195.3M— QoQ
Last fiscal yearDec 2025
$28.88M— YoY
LTMJun 2026
$224.18M— YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR+79.4%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
28.88M USD
Year-over-year change
—

Debt Repayment vs competitors

How VRDN compares with its peers on the latest reported figures

  • VRDN's LTM Jun 2026 debt repayment of $224.18M is the largest of the 4 companies compared; the peer median is $99K.
  • Debt repayment amounts to 315.2% of revenue for VRDN, versus a peer median of 1.3%.
VRDN Competitors Peer median
Debt Repayment for VRDN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VRDNViridian Therapeutics, Inc.LTM Jun 2026$224.18M —+79.4%315.2%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$3.23M -1764.2%+9.5%970.3%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$99K -29.3%—1.3%
OCULOcular Therapeutix, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding VRDN) $99K-896.8%+9.5%1.3%

Competitors are the stored peer set for VRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(79.41M)(129.87M)(237.73M)(269.95M)(342.6M)
Depreciation & Amortization120K255K522K540K460K
Deferred Income Tax00000
Stock-Based Compensation14.47M19.77M67.17M42.15M44.3M
Change in Working Capital1.72M15.96M(9.43M)9.6M23.03M
Accounts Receivables(451K)349K0102K0
Inventory00000
Accounts Payables1.66M11.52M(12.04M)(73K)6.56M
Other Working Capital520K4.09M2.62M9.57M16.47M
Other Non-Cash Items8.52M54K(4.71M)(14.66M)(1.58M)
Operating Cash Flow(54.58M)(93.84M)(184.17M)(232.32M)(276.39M)
Capital Expenditures(338K)(797K)(898K)(511K)(495K)
Acquisitions (Net)00000
Purchases of Investments(188.43M)(223.26M)(407.88M)(695.07M)(579.28M)
Sales of Investments114.4M108.94M314.53M466.93M542.21M
Other Investing Activities79K0000
Investing Cash Flow(74.29M)(115.13M)(94.25M)(228.65M)(37.56M)
Debt Repayment05M15M028.88M
Common Stock Issued114.24M291.87M125.07M453.66M348.33M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(5.93M)(18.63M)9.41M(20.92M)49.54M
Financing Cash Flow125.28M322.24M225.67M457.74M426.74M
Effect of Forex Changes00000
Net Change in Cash(3.6M)113.28M(52.75M)(3.23M)112.79M
Free Cash Flow(54.92M)(94.64M)(185.07M)(232.83M)(276.89M)

Viridian Therapeutics, Inc.

NASDAQ:VRDN

Intrinsic Alpha fair value

Locked

Current Price

$30.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.